Clinical Trial Update: Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial compared 12 weeks versus 24 weeks of extended treatment in chronic hepatitis C patients (genotypes 2/3); the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: HepNet Study House, German Liverfoundation | Conditions: Hepatitis C, Chronic | Phase 4 | Status: TERMINATED